Skip to main content

Table 1 Mutation types of IDH and TERT in each histological type in Cohort 1 and 2, each

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

  Cohort 1 Cohort 2
Histology DA AA GBM OA AOA OL AO All GBMa
Total 63 106 337 67 103 47 35 758 193
IDH1/2 n(%) R132H 36 (57) 38 (36) 16 (5) 56 (84) 59 (57) 42 (89) 27 (77) 274 (36) 0 (0)
Other mutation 2 (3) 2 (2) 0 (0) 2 (3) 2 (2) 3 (6) 1 (3) 12 (2) 0 (0)
All mutation 38 (60) 40 (38) 16 (5) 58 (87) 61 (59) 45 (96) 28 (80) 286 (38) 0 (0)
TERT n(%) C228T 12 (19) 29 27) 136 (40) 27 (40) 30 (29) 27 (57) 17 (49) 278 (37) 94 (49)
C250T 5 (8) 6 (6) 58 (17) 6 (9) 15 (15) 12 (26) 9 (26) 111 15) 21 (11)
C228T&C250T 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0)
All mutation 18 (29) 35 (33) 194 (58) 33 (49) 45 (44) 39 (83) 26 (74) 390 (51) 115 (60)
1p/19q n(%) Total 1p/19q loss 9/63 (14) 6/106 (6) 6/336 (2) 27/67 (40) 32/103 (31) 41/47 (87) 27/35 (77) 148/757 (20) N/A
MGMT n(%) Methylated 35/62 (56) 45/106 (42) 126/336 (38) 44/66 (67) 67/103 (65) 39/47 (83) 30/35 (86) 386/755 (51) 66/193 (34)
H3.3/H3.1 n(%) K27M 2/34 (6) 6/71 (9) 12/316 (4) 0/20 (0) 1/47 (2) 0/12 (0) 0/10 (0) 21/510 (4) 0/193 (0)
Other mutation 0/34 (0) 0/71 (0) 0/316 (0) 0/20 (0) 1/47 (2) 1/12 (8) 0/10 (0) 2/510 (0.4) 0/193 (0)
BRAF (V600) n(%) V600E 1/34 (3) 3/70 (4) 8/313 (3) 0/20 (0) 0/47 (0) 0/12 (0) 0/10 (0) 12/506 (2) 4/193 (2)
CDKN2A n(%) Homozygous Del 3/48 (6) 13/74 (18) 86/229 (37) 0/42 (0) 11/64 (17) 0/28 (0) 3/20 (15) 116/505 (23) N/A
Heterozygous Del 2/48 (4) 15/74 (20) 40/229 (17) 1/42 (2) 9/64 (14) 2/28 (7) 3/20 (15) 72/505 (14) N/A
  1. a IDH1/2 mutated cases were excluded for Cohort 2 (see Materials and methods in the manuscript)
  2. AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligoastrocytoma, DA diffuse astrocytoma, Del Deletion, GBM glioblastoma, N/A not available, OA oligoastrocytoma, OL oligodendroglioma